Regulatory News In Brief

Physician Payment Sunshine Act finally goes to OMB. FDA signs regulatory agreements with Brazil, Australia and Canada. More regulatory news.

The Physician Payments Sunshine Act finally cleared CMS review Nov. 27 and was sent to the Office of Management and Budget for final review. The rule, passed as part of the Affordable Care Act, governs the transparency of industry gifts to health care professionals. CMS has been widely criticized for its delays in clearing the rule. (See Also see "CMS Catches Criticism For Continued Delays With Sunshine Rule" - Medtech Insight, 17 September, 2012..) On Nov. 18, Medtronic and the Pew Charitable Trusts sent a joint letter to CMS Acting Administrator Marilyn Tavenner urging that final regulations be released no later than this December so that manufacturers can begin implementing procedures for collecting payment information. The law is supposed to go into effect Jan. 1, 2013, with manufacturers reporting gift data by March 31, but delays in issuing final regulations have made these deadlines unfeasible, the groups wrote.

FDA Commissioner Margaret Hamburg signed two cooperative agreements with international regulatory agencies at the 7th Summit of Heads of Medicines Regulatory Agencies in Manaus, Brazil, held Nov. 26-29, according to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.

UK Take Care! Regulatory And Market Access Reforms Must Not Shut Out Medtech Growth

 
• By 

Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.

Zika Virus Test Among 4 New FDA Device Classifications

 
• By 

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

Industry Execs Talk Tariff Turbulence During MD&M East

 

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

More from Policy & Regulation

Zika Virus Test Among 4 New FDA Device Classifications

 
• By 

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

FDA Draft Guidance Introduces Electric Submission For Q-Sub Process

 

The US FDA says its updated draft guidance represents one of several steps the agency is taking to develop electronic submission templates for the medical device industry. The document introduces stakeholders to currently available resources for supporting their pre-subs to the agency.

Industry Execs Talk Tariff Turbulence During MD&M East

 

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.